trending Market Intelligence /marketintelligence/en/news-insights/trending/Mo1ogW3hsIkD9zei_2wstA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

ATAI Life buys majority stake in Perception Neuroscience alongside PE firms

Banking Essentials Newsletter - November Edition

University Essentials | COVID-19 Economic Outlook in Banking: Rates and Long-Term Expectations: Q&A with the Experts

Estimating Credit Losses Under COVID-19 and the Post-Crisis Recovery

StreetTalk – Episode 70: Banks' Liquidity Conundrum Could Fuel M&A Activity


ATAI Life buys majority stake in Perception Neuroscience alongside PE firms

Private equity firm Morgan Noble Healthcare Partners, venture capital firm Subversive Capital LLC and life-sciences investor WPSS Investments co-invested alongside biotechnology company ATAI Life Sciences AG to acquire a majority stake in biopharmaceutical company Perception Neuroscience for an undisclosed amount.

Perception founders Jonathan Sporn and Jay Kranzler will retain minority stakes in the company, which is developing a ketamine-based rapid-acting antidepressant drug. ATAI said the arketamine drug is expected to be more effective than current FDA-approved antidepressants, which can take weeks to become effective.

Morgan Noble invests in transformative healthcare treatments, and Subversive Capital works with companies requiring sophisticated government and regulatory assistance.

PJT Partners advised on the transaction.